Trial Outcomes & Findings for Fall Epidemic Viral Pediatric Study (NCT NCT01192178)

NCT ID: NCT01192178

Last Updated: 2017-01-18

Results Overview

An asthma exacerbation was defined as deterioration of asthma that required the use of outpatient oral/parenteral corticosteroids (tablets, suspensions, or injection) or an urgent care, hospitalization, or emergency room (ER) visit due to asthma that required oral/parenteral corticosteroids. Two exacerbations (out of a total of 51) were excluded: (1) one exacerbation occurred within 7 days of the resolution of an earlier one, and, per protocol, was combined with the previous exacerbation; and (2) one exacerbation occurred post treatment.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

339 participants

Primary outcome timeframe

From Baseline (Week 1) until the end of treatment (up to Week 16)

Results posted on

2017-01-18

Participant Flow

Participant milestones

Participant milestones
Measure
FSC DISKUS 100/50 mcg BID
Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) at a dose of 100/50 micrograms (mcg) administered as one inhalation twice daily (BID) for 16 weeks
FP DISKUS 100 mcg BID
Fluticasone Propionate (FP) DISKUS 100 mcg administered as one inhalation BID for 16 weeks
Overall Study
STARTED
171
168
Overall Study
COMPLETED
147
145
Overall Study
NOT COMPLETED
24
23

Reasons for withdrawal

Reasons for withdrawal
Measure
FSC DISKUS 100/50 mcg BID
Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) at a dose of 100/50 micrograms (mcg) administered as one inhalation twice daily (BID) for 16 weeks
FP DISKUS 100 mcg BID
Fluticasone Propionate (FP) DISKUS 100 mcg administered as one inhalation BID for 16 weeks
Overall Study
Withdrawal by Subject
6
10
Overall Study
Protocol Violation
10
3
Overall Study
Physician Decision
2
4
Overall Study
Lost to Follow-up
3
3
Overall Study
Adverse Event
2
1
Overall Study
Lack of Efficacy
1
2

Baseline Characteristics

Fall Epidemic Viral Pediatric Study

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
FSC DISKUS 100/50 mcg BID
n=171 Participants
Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) at a dose of 100/50 micrograms (mcg) administered as one inhalation twice daily (BID) for 16 weeks
FP DISKUS 100 mcg BID
n=168 Participants
Fluticasone Propionate (FP) DISKUS 100 mcg administered as one inhalation BID for 16 weeks
Total
n=339 Participants
Total of all reporting groups
Age, Continuous
7.5 Years
STANDARD_DEVIATION 2.11 • n=99 Participants
7.4 Years
STANDARD_DEVIATION 2.08 • n=107 Participants
7.4 Years
STANDARD_DEVIATION 2.09 • n=206 Participants
Gender
Female
63 Participants
n=99 Participants
56 Participants
n=107 Participants
119 Participants
n=206 Participants
Gender
Male
108 Participants
n=99 Participants
112 Participants
n=107 Participants
220 Participants
n=206 Participants
Race/Ethnicity, Customized
African American/African Heritage
27 participants
n=99 Participants
33 participants
n=107 Participants
60 participants
n=206 Participants
Race/Ethnicity, Customized
American Indian or Alaska Native
2 participants
n=99 Participants
0 participants
n=107 Participants
2 participants
n=206 Participants
Race/Ethnicity, Customized
Asian
8 participants
n=99 Participants
6 participants
n=107 Participants
14 participants
n=206 Participants
Race/Ethnicity, Customized
American Indian or Alaska Native and White
1 participants
n=99 Participants
0 participants
n=107 Participants
1 participants
n=206 Participants
Race/Ethnicity, Customized
White
129 participants
n=99 Participants
127 participants
n=107 Participants
256 participants
n=206 Participants
Race/Ethnicity, Customized
African American/African Heritage and White
1 participants
n=99 Participants
1 participants
n=107 Participants
2 participants
n=206 Participants
Race/Ethnicity, Customized
Asian & Native Hawaiian or Other Pacific Islander
1 participants
n=99 Participants
0 participants
n=107 Participants
1 participants
n=206 Participants
Race/Ethnicity, Customized
Asian and White
2 participants
n=99 Participants
0 participants
n=107 Participants
2 participants
n=206 Participants
Race/Ethnicity, Customized
Native Hawaiian or Other Pacific Islander & White
0 participants
n=99 Participants
1 participants
n=107 Participants
1 participants
n=206 Participants

PRIMARY outcome

Timeframe: From Baseline (Week 1) until the end of treatment (up to Week 16)

Population: Intent-to-Treat (ITT) Population: all participants randomized to treatment. Only those participants who reported \>=1 exacerbation were analyzed.

An asthma exacerbation was defined as deterioration of asthma that required the use of outpatient oral/parenteral corticosteroids (tablets, suspensions, or injection) or an urgent care, hospitalization, or emergency room (ER) visit due to asthma that required oral/parenteral corticosteroids. Two exacerbations (out of a total of 51) were excluded: (1) one exacerbation occurred within 7 days of the resolution of an earlier one, and, per protocol, was combined with the previous exacerbation; and (2) one exacerbation occurred post treatment.

Outcome measures

Outcome measures
Measure
FSC DISKUS 100/50 mcg BID
n=21 Participants
Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) at a dose of 100/50 micrograms (mcg) administered as one inhalation twice daily (BID) for 16 weeks
FP DISKUS 100 mcg BID
n=20 Participants
Fluticasone Propionate (FP) DISKUS 100 mcg administered as one inhalation BID for 16 weeks
Total Number of Asthma Exacerbations Reported During the Treatment Period
24 Number of asthma exacerbations
25 Number of asthma exacerbations

SECONDARY outcome

Timeframe: Baseline (Week 1) and Peak Viral Period ([period during which the greatest number of viral infections is expected] from 30 August 2010 through the end of the treatment period [up to Week 16])

Population: ITT Population. Only those participants with moderate or severe URTS or a confirmed RV infection were analyzed.

Participants recorded their asthma symptom score over the previous 24 hours (during the day and the previous night) using the following 6-point scale: 0=No symptoms; 1=Symptoms for 1 short period; 2=Symptoms for \>=2 short periods; 3=Symptoms for most of the day/previous night that did not affect normal daily activities; 4=Symptoms for most of the day/previous night that affected normal daily activities; 5=Symptoms so severe that participant could not perform normal daily activities. The Baseline mean asthma symptom score was calculated as the average score over 7 days prior to Week 1, Visit 2.

Outcome measures

Outcome measures
Measure
FSC DISKUS 100/50 mcg BID
n=106 Participants
Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) at a dose of 100/50 micrograms (mcg) administered as one inhalation twice daily (BID) for 16 weeks
FP DISKUS 100 mcg BID
n=104 Participants
Fluticasone Propionate (FP) DISKUS 100 mcg administered as one inhalation BID for 16 weeks
Mean Asthma Symptom Scores, as an Indicator of Severity, Associated With the Presence of Moderate or Severe Upper Respiratory Tract Symptoms (URTS) or a Confirmed Rhinovirus (RV) Infection at Baseline and During the Peak Viral Period
Baseline, n=105, 104
0.2 Scores on a scale
Standard Deviation 0.41
0.2 Scores on a scale
Standard Deviation 0.39
Mean Asthma Symptom Scores, as an Indicator of Severity, Associated With the Presence of Moderate or Severe Upper Respiratory Tract Symptoms (URTS) or a Confirmed Rhinovirus (RV) Infection at Baseline and During the Peak Viral Period
Peak Viral Period, n=106, 104
0.5 Scores on a scale
Standard Deviation 0.84
0.4 Scores on a scale
Standard Deviation 0.70

SECONDARY outcome

Timeframe: Peak Viral Period (from 30 August 2010 through the end of treatment [up to Week 16])

Population: ITT Population. Only those participants with relevant data defining a worsening asthma day during the peak viral period and with moderate or severe URTS or a confirmed RV infection were analyzed.

A worsening asthma day is one on which any of the following occurred: rescue albuterol use above baseline, use of oral/parenteral corticosteroids for asthma, use of asthma medication other than study medication, asthma symptom scores \>=3, nighttime awakenings, unscheduled health care visits, or missed school due to asthma. The duration of worsening asthma is the number of consecutive worsening asthma days after the date of a URTS score of 2 (moderate) or 3 (severe) or collection of a mucus sample containing RV (whichever occurred first). Each span of consecutive days is a participant interval.

Outcome measures

Outcome measures
Measure
FSC DISKUS 100/50 mcg BID
n=121 Participants
Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) at a dose of 100/50 micrograms (mcg) administered as one inhalation twice daily (BID) for 16 weeks
FP DISKUS 100 mcg BID
n=145 Participants
Fluticasone Propionate (FP) DISKUS 100 mcg administered as one inhalation BID for 16 weeks
Mean Duration of Worsening Asthma Symptoms Associated With the Presence of Moderate or Severe URTS or a Confirmed RV Infection
4.1 Days per participant interval
Standard Error 0.18
4.0 Days per participant interval
Standard Error 0.17

SECONDARY outcome

Timeframe: Peak Viral Period (from 30 August 2010 through the end of treatment [up to Week 16])

Population: ITT Population. Only those participants who reported \>=1 exacerbation were analyzed. Only those participants with moderate or severe URTS or a confirmed RV infection were analyzed.

Each participant (with assistance from the parent/legal guardian as needed) was instructed to keep an electronic diary (eDiary) with record of daily URTS symptoms that included: runny nose, sneezing, nasal congestion, and sore throat. Based on the best-described aggregate URTS during the previous 24 hours, participants rated symptoms as: 0 = Not present; 1 = Mild, clearly present; 2 = Moderately severe, uncomfortable; and 3 = Severe, interfering with sleep or activity. Mucus samples were collected and analyzed for RVwhen the eDiary alerted for moderate/severe URTS.

Outcome measures

Outcome measures
Measure
FSC DISKUS 100/50 mcg BID
n=5 Participants
Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) at a dose of 100/50 micrograms (mcg) administered as one inhalation twice daily (BID) for 16 weeks
FP DISKUS 100 mcg BID
n=7 Participants
Fluticasone Propionate (FP) DISKUS 100 mcg administered as one inhalation BID for 16 weeks
Number of Asthma Exacerbations Associated With the Presence of Moderate or Severe URTS or a Confirmed RV Infection During the Peak Viral Period
5 Number of asthma exacerbations
7 Number of asthma exacerbations

SECONDARY outcome

Timeframe: Peak Viral Period (from 30 August 2010 through the end of treatment [up to Week 16])

Population: ITT Population. Only those participants who recorded data during the Peak Viral Period, had a treatment stop date with a defined Peak Viral Period, and had available data on all days on which data were recorded were analyzed.

An asthma-control day was defined as a day without any of the following: rescue albuterol use, use of oral/parenteral corticosteroids for asthma, use of asthma medication other than double-blind study treatment, asthma symptom score \>0, nighttime awakenings due to asthma, unscheduled health care visits (defined as home visits, office visits, or urgent care visits), ER visits, hospitalizations for asthma, or school absenteeism due to asthma. The percentage of asthma-control days = the number (No.) of asthma-control days divided by the No. of days of treatment exposure, multiplied by 100.

Outcome measures

Outcome measures
Measure
FSC DISKUS 100/50 mcg BID
n=161 Participants
Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) at a dose of 100/50 micrograms (mcg) administered as one inhalation twice daily (BID) for 16 weeks
FP DISKUS 100 mcg BID
n=156 Participants
Fluticasone Propionate (FP) DISKUS 100 mcg administered as one inhalation BID for 16 weeks
Mean Percentage of Asthma-control Days
48.3 Percentage of days
Standard Error 1.51
49.7 Percentage of days
Standard Error 1.54

SECONDARY outcome

Timeframe: Peak Viral Period (from 30 August 2010 through the end of treatment [up to Week 16])

Population: ITT Population. Only those participants who recorded data during the Peak Viral Period, had a treatment stop date with a defined Peak Viral Period, and had available data on all days on which data were recorded were analyzed.

An EF day was defined as a day without any of the following: rescue albuterol use, use of oral/parenteral corticosteroids for asthma, use of asthma medication other than study treatment, asthma symptom score \>0, nighttime awakenings due to asthma, unscheduled health care visits (defined as home visits, office visits, or urgent care visits), ER visits, hospitalizations for asthma, school absenteeism due to asthma, or morning peak expiratory flow (measure of maximum airflow) \<80% of baseline. Percentage of EF days=No. of EF days divided by No. of days of treatment exposure, multiplied by 100.

Outcome measures

Outcome measures
Measure
FSC DISKUS 100/50 mcg BID
n=161 Participants
Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) at a dose of 100/50 micrograms (mcg) administered as one inhalation twice daily (BID) for 16 weeks
FP DISKUS 100 mcg BID
n=155 Participants
Fluticasone Propionate (FP) DISKUS 100 mcg administered as one inhalation BID for 16 weeks
Mean Percentage of Episode-free (EF) Days
42.4 Percentage of days
Standard Error 1.55
44.5 Percentage of days
Standard Error 1.61

SECONDARY outcome

Timeframe: Peak Viral Period (from 30 August 2010 through the end of treatment [up to Week 16])

Population: ITT Population. Only those participants who recorded data during the Peak Viral Period and had a treatment stop date with a defined Peak Viral Period were analyzed.

A symptom-free day was defined as a day during the Peak Viral Period on which the asthma symptom score was zero. The daily asthma symptom score (measured during the day and the previous night) was reported on a 6-point scale (ranging from 0=no symptoms to 5=severe symptoms). Percentage of symptom-free days was defined as the number of days during the Peak Viral Period on which the asthma symptom score=0, divided by the number of days in that same period on which non-missing values were recorded, multiplied by 100.

Outcome measures

Outcome measures
Measure
FSC DISKUS 100/50 mcg BID
n=161 Participants
Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) at a dose of 100/50 micrograms (mcg) administered as one inhalation twice daily (BID) for 16 weeks
FP DISKUS 100 mcg BID
n=157 Participants
Fluticasone Propionate (FP) DISKUS 100 mcg administered as one inhalation BID for 16 weeks
Mean Percentage of Symptom-free Days
90.1 Percentage of days
Standard Deviation 15.89
91.1 Percentage of days
Standard Deviation 13.18

SECONDARY outcome

Timeframe: Peak Viral Period (from 30 August 2010 through the end of treatment [up to Week 16])

Population: ITT Population. Only those participants who recorded data during the Peak Viral Period and had a treatment stop date with a defined Peak Viral Period were analyzed.

A rescue-free day was defined as a day during the Peak Viral Period on which no puffs of rescue medication were recorded. Percentage of rescue-free days was defined as the number of days during the Peak Viral Period on which no puffs of rescue medication were recorded, divided by the number of days in that same period on which non-missing values were recorded, multiplied by 100.

Outcome measures

Outcome measures
Measure
FSC DISKUS 100/50 mcg BID
n=161 Participants
Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) at a dose of 100/50 micrograms (mcg) administered as one inhalation twice daily (BID) for 16 weeks
FP DISKUS 100 mcg BID
n=157 Participants
Fluticasone Propionate (FP) DISKUS 100 mcg administered as one inhalation BID for 16 weeks
Mean Percentage of Rescue-free Days
92.1 Percentage of days
Standard Deviation 16.60
91.7 Percentage of days
Standard Deviation 14.68

Adverse Events

FSC DISKUS 100/50 mcg BID

Serious events: 2 serious events
Other events: 85 other events
Deaths: 0 deaths

FP DISKUS 100 mcg BID

Serious events: 1 serious events
Other events: 84 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
FSC DISKUS 100/50 mcg BID
n=171 participants at risk
FSC at a dose of 100/50 mcg administered as one inhalation BID for 16 weeks
FP DISKUS 100 mcg BID
n=168 participants at risk
FP DISKUS 100 mcg administered as one inhalation BID for 16 weeks
Infections and infestations
Gastroenteritis
0.58%
1/171
0.00%
0/168
Infections and infestations
Pneumonia respiratory syncytialviral
0.58%
1/171
0.00%
0/168
Nervous system disorders
Syncope
0.00%
0/171
0.60%
1/168
Respiratory, thoracic and mediastinal disorders
Respiratory distress
0.58%
1/171
0.00%
0/168
Respiratory, thoracic and mediastinal disorders
Status asthmaticus
0.58%
1/171
0.00%
0/168

Other adverse events

Other adverse events
Measure
FSC DISKUS 100/50 mcg BID
n=171 participants at risk
FSC at a dose of 100/50 mcg administered as one inhalation BID for 16 weeks
FP DISKUS 100 mcg BID
n=168 participants at risk
FP DISKUS 100 mcg administered as one inhalation BID for 16 weeks
Infections and infestations
Upper respiratory tract infection
17.5%
30/171
18.5%
31/168
Infections and infestations
Nasopharyngitis
8.8%
15/171
11.9%
20/168
Infections and infestations
Sinusitis
6.4%
11/171
1.8%
3/168
Respiratory, thoracic and mediastinal disorders
Cough
15.2%
26/171
12.5%
21/168
Reproductive system and breast disorders
Nasal congestion
8.8%
15/171
7.7%
13/168
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
8.2%
14/171
7.1%
12/168
Nervous system disorders
Headache
14.6%
25/171
16.7%
28/168
General disorders
Pyrexia
11.7%
20/171
9.5%
16/168

Additional Information

GSK Response Center

GlaxoSmithKline

Phone: 866-435-7343

Results disclosure agreements

  • Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
  • Publication restrictions are in place

Restriction type: OTHER